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Prevalence of and risk factors for peripheral arterial disease in the
United States: Results from the National Health and Nutrition Exam-
ination Survey, 1999-2000
Selvin E, Erlinger TP. Circulation 2004;110:738-43.
Conclusion: Peripheral arterial disease (PAD) affects more than 5
million adults in the United States, increases dramatically with age, and
disproportionately affects blacks. A large majority of patients with PAD have
one or more cardiovascular risk factors.
Summary: Data from 2174 participants in the 1999-2000 National
Health and Nutrition Examination Survey who were age 40 years or older
were analyzed. PADwas determined to be present if the ankle brachial index
was less than 0.9 in either leg. The prevalence of PAD in the population of
adults aged over 40 in the United States was 4.3% (95% confidence interval
[CI], 3.1% to 5.1%) corresponding to approximately 5 million individuals.
Among subjects aged 70 years or older, the prevalence was 14.5% (95% CI,
10.8% to 18.2%). A gender- and age-adjusted logistic regression analysis
indicated black race/ethnicity (odds ratio [OR], 2.83; 95% CI, 1.48 to
5.42), current smoking (OR, 4.46; 95% CI, 2.25 to 8.84), diabetes mellitus
(OR, 2.72; 95% CI, 1.03 to 7.12), hypertension (OR, 1.75; 95% CI, 0.97 to
3.13), hypercholesterolemia (OR, 1.68; 95% CI, 1.09 to 2.57), and dimin-
ished kidney function (OR, 2.00; 95%CI, 1.08 to 3.70) were associated with
PAD.One or more cardiovascular risk factors were present in 95% of persons
with PAD. Elevated C-reactive protein levels and fibrinogen were also
associated with PAD.
Comment: If anything, the study likely underestimates the prevalence
of PAD, as patients with severe risk factors or severe chronic diseasemay have
been less likely to participate in the survey.
Comparison of endovascular aneurysm repair with open repair in
patients with abdominal aortic aneurysms (EVAR Trial I), thirty-day
operative mortality results: Randomised controlled trial
EVAR Trial Participants. Lancet 2004;364:843-8.
Conclusion: In patients with large abdominal aortic aneurysms (AAA)
anatomically suitable for either open or endovascular aneurysm repair
(EVAR), EVAR reduces the 30-day operative mortality rate by two thirds
compared with open repair.
Summary: This is a large, multicenter, prospective randomized
study from 41 British hospitals comparing EVAR to open aneurysm
repair. Between 1999 and 2003, 1082 elective (nonemergency) patients
were randomized to receive either EVAR (n  543) or open AAA repair
(n  539). All patients were at least 60 years of age with aneurysm
diameters of 5.5 cm or more. All patients were required to be medically
and anatomically suitable for either open AAA repair or EVAR. This is a
preliminary report of this study in which the primary outcome measure is
all-cause mortality. The analysis presented in this paper is operative
mortality by intension to treat and a secondary analysis in patients
actually treated per protocol.
The study enrolled 983 men and 99 women with a mean age of 74
years  6 years and a mean AAA diameter of 6.5 cm  1 cm. Of these
patients, 1047 (97%) underwent AAA repair, and 93% (n  1008) received
their allocated treatment. In the EVAR group, 30-day mortality was 1.7%
(9/521) versus 4.7% (24/516) in the open repair group (odds ratio [OR],
0.35; 95% confidence interval [CI], 0.16 to 0.77; P  0.009). With a per
protocol analysis, 30-day mortality for EVAR was 1.6% (8/512) versus 4.6%
(23/496) for open repair (OR, 0.33; 95% CI, 0.15 to 0.74; P  .007).
EVAR patients received more secondary interventions than open aneurysm
repair patients (9.8% vs 5.8%, P  .02).
Comment: This trial and the Dutch Randomised Endovascular Aneu-
rysm Management (DREAM) Trial (see below) (N Engl J Med 2004;351:
1607-18) deliver a clear message. Endovascular AAA repair has a lower risk
for 30-day mortality than open aneurysm repair. The durability of EVAR
remains in doubt, however, and there are data to suggest that the ongoing
risk of rupture with EVAR, even though low, will rapidly lead to obliteration
of the perioperative benefit of operative mortality. The need for secondary
procedures in the EVAR patients and the costs of ongoing treatment and
monitoring also remain significant questions. At this point the results of this
trial and the Dream Trial do not mandate change in clinical practice.
A randomized trial comparing conventional and endovascular repair of
abdominal aortic aneurysms
Prinssen M, Verhoeven ELG, Buth J, et al. N Engl J Med 2004;351:
1607-18.
Conclusion: The authors conclude that endovascular repair is prefer-
able to open repair in patients who have an abdominal aortic aneurysm
(AAA) that is at least 5 cm in diameter. The authors’ data do not substantiate
this conclusion (see AComment@ below).
Summary: This was a multicenter randomized trial that compared
endovascular repair and open repair of AAAs in 345 patients where the
aneurysms measured at least 5 cm in diameter in patients who were candi-
dates for either endovascular or open repair. End points included operative
(30-day) mortality and two composite end points consisting of either
operative mortality and severe complications or operative mortality and
moderate or severe complications.
Eight of 174 patients undergoing open repair died within 30 days
(operative mortality, 6.4%) of the procedure. Two of 171 patients undergo-
ing endovascular repair died within 30 days (operative mortality, 1.2%) of
the procedure (risk ratio [RR], 3.9; 95% confidence interval [CI], 0.9 to
32.9, P  .10). The combined rate of operative mortality and severe
complications was 4.7% in the endovascular group versus 9.8% in the open
repair group (RR, 2.1; 95% CI, 0.92 to 5.4; P .10). The combined rate of
operative mortality and moderate or severe complications was 23.6% in the
open repair group versus 18.1% in the endovascular repair group (RR, 1.3;
95% CI, 0.9 to 2.0; P  0.23.
Comment: This study and the larger Endovascular Aneurysm Repair
(EVAR) trial (Lancet 2004;364:843-8) both document lowered 30-day
mortality rates with endovascular aneurysm repair versus open AAA repair.
However, it is not possible to truly compare endovascular repair and open
repair without long-term data regarding the risk of aneurysm rupture, graft
complications, need for follow-up, and cost. There are also indications that
larger aneurysms repaired with endovascular techniques may not do as well
in the long run as the smaller aneurysms (JVS 2003;137:1206-12). All of
these concerns, in combination with the recent suppression of a US Food
and Drug Administration Report under pressure from industry (JVS 2004;
40:209-10), combine to lead one to question the authors’ conclusions in the
abstract of this article. An insightful editorial on these arguments by Dr
Frank Lederle is included in the same issue of the New England Journal of
Medicine ( N Engl JMed 2004;351:1677-9) and is recommended to readers
of the Journal of Vascular Surgery.
Improved vascular gene transfer with a helper-dependent adenoviral
vector
Wen S, Graf S, Massey P.G., et al. Circulation 2004;110:1484-91.
Conclusion: A third-generation or “helper-dependent” adenoviral
vector can stably express a therapeutic gene in the vascular wall for more than
8 weeks.
Summary: Adenoviral vectors can be used to transfer genes into the
vascular wall. The utility of adenoviral vectors for vascular gene transfer has
been limited by host inflammatory response and limited periods of expres-
sion of the gene. In this study, a third-generation or helper-dependent
adenoviral vector that has achieved prolonged recombinant gene expression
in liver and muscle with minimal associated inflammation was tested for
vascular gene transfer. A helper-dependent adenoviral vector expressing
rabbit urokinase plasminogen activator (HD-AduPA) was studied. The
third-generation helper-dependent adenoviral vector expressing HD-
AduPA was compared with a first-generation adenovirus also expressing
rabbit urokinase plasminogen activator (FG-AduPA). Urokinase plasmino-
gen activator and vector-delivered DNAwere measured in arteries harvested
3 to 56 days after gene transfer. Vector-specific mRNA, neointimal forma-
tion, and vascular inflammation were examined 14 days after gene transfer.
Urokinase plasminogen activator expression was lost and vector DNA
declined rapidly in arteries treated with FG-AduPA. However, urokinase
plasminogen activator expression and vector DNA persisted in HD-AduPA
arteries for 56 days or more. Expression was stable from 14 to 56 days.
Increased urokinase plasminogen activator in HD-AduPA arteries was also
associated with high levels of vector-specific urokinase plasminogen activator
and mRNA. There was less information in arteries treated with HD-AduPA
than those treated with FG-AduPA. There was also less neointimal forma-
tion in the HD-AduPA–treated arteries.
Comment: The Holy Grail of gene therapy is to transfer a therapeutic
gene to an individual requiring the gene product with subsequent stable
expression of the gene product and minimal adverse reaction of the host.
Research such as this is crucial to making gene therapy a therapeutic reality.
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